Cellectis' UCART22 product candidate for ALL treatment receives US FDA orphan drug and rare paediatric disease ...
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that the US Food and Drug Administration (FDA) has granted orphan drug and rare paediatric disease …